Teva spared payout to GSK over patent infringement dispute

pharmafile | March 29, 2018 | News story | Sales and Marketing Coreg, GSK, GlaxoSmithKline, Teva, carvedilol, heart failure, pharma 

Teva has been spared a sizeable payout to GlaxoSmithKline after a federal judge overturned a US jury verdict demanding that the Israeli firm hand over $235 million in damages related to infringement of one of the latter’s patents.

The original ruling, made in June last year, judged that Teva had caused doctors to breach GSK’s patent on its blood pressure therapy Coreg through sales of the generic version carvedilol as a substitute in the treatment of chronic heart failure. This resulted in $234.1 million in lost profits, which Teva was required to pay, plus $1.4 million in royalties.

US District Judge Leonard Stark made the new ruling, asserting that evidence did not support the view that Teva was responsible for the infringement of the patent in question over other factors.

“Without proof of causation, which is an essential element of GSK’s action, a finding of inducement cannot stand,” he said.

Judge Stark did not however overturn the earlier decision to reject Teva’s view that the patent was invalid.

Unsurprisingly, GSK were not happy with the ruling: “We are disappointed with the judge’s decision and are reviewing our options,” the company said in a statement.

Matt Fellows

Related Content


GSK’s RSV vaccine approved in EU for older adults

GSK has announced that the European Commission (EC) has authorised Arexvy, the company’s respiratory syncytial …

GSK receives FDA file acceptance for Jemperli plus chemotherapy for treating endometrial cancer

GSK has announced that the US Food and Drug Administration (FDA) has accepted the supplemental …

AstraZeneca’s Farxiga approved to reduce risk of cardiovascular death

AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Farxiga to …

Latest content